# reload+after+2024-01-20 17:43:21.014002
address1§10770 Wateridge Circle
address2§Suite 210
city§San Diego
state§CA
zip§92121-5801
country§United States
phone§858 362 6295
fax§858 362 6296
website§https://www.anaptysbio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
fullTimeEmployees§96
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Daniel R. Faga', 'age': 43, 'title': 'President, CEO & Director', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 867115, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Eric J. Loumeau', 'age': 60, 'title': 'Chief Legal Officer', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 685593, 'exercisedValue': 0, 'unexercisedValue': 1070611}, {'maxAge': 1, 'name': 'Dr. James N. Topper M.D., Ph.D.', 'age': 61, 'title': 'Advisor', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 86500, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.', 'age': 48, 'title': 'Chief Medical Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 656358, 'exercisedValue': 0, 'unexercisedValue': 718650}, {'maxAge': 1, 'name': 'Mr. Dennis M. Mulroy', 'age': 68, 'title': 'Chief Financial Officer', 'yearBorn': 1955, 'fiscalYear': 2022, 'totalPay': 448807, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Benjamin  Stone', 'title': 'Senior Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Beth  Mueller', 'title': 'Senior Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Martin  Dahl Ph.D.', 'title': 'Senior Vice President of Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Douglas A. Rich M.B.A.', 'age': 54, 'title': 'Senior Vice President of CMC', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§9
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§10
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§-0.27
priceToSalesTrailing12Months§38.06862
currency§USD
dateShortInterest§1702598400
forwardEps§-6.52
exchange§NMS
quoteType§EQUITY
shortName§AnaptysBio, Inc.
longName§AnaptysBio, Inc.
firstTradeDateEpochUtc§1485441000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3d841784-242f-31d7-bc24-dd1d6e0e95f0
gmtOffSetMilliseconds§-18000000
targetHighPrice§44.0
targetLowPrice§20.0
targetMeanPrice§27.0
targetMedianPrice§21.0
recommendationMean§2.5
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§10.626
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
